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Abstract 27 
The objective of this retrospective study was to report the clinical use of atracurium and its 28 
reversal with neostigmine in pet rabbits. The medical records of 14 rabbits undergoing 29 
anesthesia for ophthalmic surgery were located through a search of the hospital’s database. 30 
Demographic data and data pertaining the use of the neuromuscular blocker and its 31 
reversal were analysed. After intravenous administration of 0.44 ± 0.4 mg/kg atracurium, 32 
11 rabbits experienced at least one of the following cardiovascular responses: hypotension, 33 
defined as systolic arterial pressure (SAP) < 75 mmHg (n=6), hypotension with decreased 34 
heart rate (HR) (n=1), hypotension with increased HR (n=1), decreased arterial blood 35 
pressure (ABP) without hypotension (n=6), decreased ABP with decreased HR (n=1), or 36 
increased HR (n=2, ABP reading could not be taken). Two of these 11 rabbits also 37 
experienced severe intra-operative hypothermia. The neuromuscular block was monitored 38 
with a train-of-four nerve-stimulation pattern, and reversed, with intramuscular 0.01-0.045 39 
mg/kg neostigmine and 0.01-0.02 mg/kg glycopirronium, after the return of at least two out 40 
of 4 muscular twitches following nerve-stimulation. Decrease in ABP and possibly 41 
hypothermia are likely intra-operative complications when clinical doses of atracurium are 42 
administered to pet rabbits. Measures should be taken to detect their occurrence in order to 43 
treat them promptly. 44 
 45 
Introduction 46 
Rabbits are becoming increasingly popular as pets and, owing to a rise in their life 47 
expectancy over the last decades, anesthesia is becoming more frequently required for the 48 
surgical treatment of conditions that commonly affect geriatric rabbits, such as cancer and 49 
cataracts. Phacoemulsification is the surgical treatment for cataracts and it has been 50 
described for use in rabbits.1 Phacoemulsification requires that the eye is completely 51 
immobilized and centrally positioned during the procedure. Ocular immobilization is also 52 
necessary for corneal surgery and is achieved through the use of neuromuscular blocking 53 
agents (NMBAs). Pancuronium and cisatracurium have been used in New Zealand White 54 
rabbits under experimental conditions.2 However, to the best of the authors’ knowledge, 55 
the clinical use of NMBAs in pet rabbits has never been described.  56 
The aim of this retrospective investigation was to report the clinical use of atracurium 57 
and its reversal with neostigmine in 14 anesthetized pet rabbits that underwent 58 
neuromuscular blockade in preparation for cataract or corneal surgery, and to report the 59 
observed unwanted effects and peri-anesthetic complications.  60 
 61 
Materials and methods 62 
The medical records of all the rabbits undergoing general Anesthesia at the Queen Mother 63 
Hospital for Animals (Royal Veterinary College) between January 2006 and January 2016 64 
were identified through the Clinical Record Database System, and reviewed. The key 65 
word-combinations used for the preliminary search were: “rabbit + anesthesia/anesthetic”, 66 
“rabbit + anesthesia/anesthetic + atracurium/NMBAs”. The search was refined in order to 67 
exclude the files of rabbits that underwent anesthesia but did not receive a NMBA. 68 
Additionally, a list of the pet rabbits that underwent ophthalmic surgery, a common 69 
indication for performing a neuromuscular block, was provided by the senior 70 
ophthalmologist. Demographic data of the patients included in the study (sex, age, breed 71 
and Body Condition Score (BCS)), as well as the details pertaining to anesthesia and 72 
particularly the administration of the NMBA, its reversal and related side effects, were 73 
obtained from the anesthetic records and used for data analysis. Data were analysed with 74 
descriptive statistics, using commercially available programs and software (Microsoft 75 
Excel iOS 1.30, Microsoft Corporation; and SigmaStat 3.5.1, Systat Software, Inc. US). 76 
The Pearson correlation test was used to correlate the temperature at the end of the 77 
anesthetic and the duration of anesthesia.  78 
 79 
Results 80 
The preliminary file search identified 180 cases, which were reduced to 14 after manual 81 
refinement of the search. Six out of 14 rabbit cases were neutered males, 6 were neutered 82 
females, and the remaining 2 were intact females. Seven different anesthetists carried out 83 
the anesthetics, while the surgeries were performed always by the same ophthalmologist 84 
(RFS). The rabbits were aged 56 ± 4 months, weighed 2.2 [1.2-2.8] kg and their BCS was 85 
3 [2-5]/9. The represented breeds were Dwarf Lop (n=4), French Lop (n=2), Netherland 86 
Dwarf (n=1), Lop Eared (n=1), and Lion-head (n=1), with the remaining rabbits being 87 
mixed-breeds. The surgical procedures were phacoemulsification (n=13), of which one 88 
also included an iridal abscess removal, and another one that also included an automated 89 
vitrectomy, and traumatic corneal laceration repair (n=1). Topical local Anesthesia (EMLA 90 
cream, AstraZeneca UK) was used to facilitate catheterization of the auricular vein. 91 
Thereafter, buprenorphine (Buprecare, Animalcare UK; dose: 0.02 [0.01-0.03] mg/kg) and 92 
midazolam (Midazolam hydrochloride, Hameln Pharmaceuticals UK; dose: 0.3 [0.2-0.3] 93 
mg/kg) were used, either intramuscularly (IM; n=10) or intravenously (IV; n=4), to 94 
premedicate all the rabbits. Five rabbits received additional medetomidine (Domitor, Pfizer 95 
UK; dose: 0.01 [0.005-0.02] mg/kg), either IM (n=4) or IV (n=1), to deepen the level of 96 
sedation. Anesthesia was induced with either alfaxalone (n=10; Alfaxan, Jurox Australia; 97 
dose: 2 [1-2] mg/kg), propofol (Diprivan, AstraZeneca UK; n=2; 2 mg/kg) or ketamine 98 
(Ketamidor, Chanelle UK; n=2; 3 mg/kg), IV, and maintained with either sevoflurane 99 
(SevoFlo, Abbott UK; n=10; end-tidal (ET): 2 [1.6-4.7] per cent) or isoflurane (IsoFlo, 100 
Abbott UK; n=4; ET: 1.2 [1.1-1.9] per cent) in oxygen following endotracheal intubation 101 
(ETT size: 2 [2-3] mm). Intra-operatively, atracurium (Tracrium, GlaxoSmithKline UK) 102 
was administered IV as boluses (total dose: 0.44 ± 0.4 mg/kg) to the rabbits to allow 103 
myorelaxation of the peri-ocular muscles. The initial atracurium dose ranged between 0.05 104 
and 0.3 mg/kg, with the anesthetist deciding on a particular dose based on the estimated 105 
duration of the surgery. The degree of neuromuscular block was monitored during 106 
anesthesia with a train-of-four electrical stimulation pattern (TOF-watch SX, Organon US), 107 
with the electrodes positioned over the proximal (positive pole) and distal (negative pole) 108 
ends of the peroneal nerve in one leg. Other monitoring consisted of ECG, arterial blood 109 
pressure (ABP) measurement with either the Doppler probe positioned over the palmar 110 
metatarsal artery (n=13; systolic blood pressure (SAP)), or invasively, via auricular artery 111 
catheterization (n=1; systolic, mean and diastolic blood pressures), capnography, gas 112 
analyzer and body temperature measured rectally. In each rabbit, a drop of a topical 113 
anesthetic (Proxymetacaine Hydrochloride 0.5%, Minims UK) was instilled twice, two to 114 
four minutes apart, at the start of each procedure. Eleven out of 14 rabbits experienced at 115 
least one cardiovascular response to atracurium during the anesthetic. The observed 116 
cardiovascular responses were the following: hypotension (defined as SAP < 75 mmHg)3 117 
(n=6), hypotension with decreased heart rate (HR) (n=1), hypotension with increased HR 118 
(n=1), decreased ABP without hypotension (n=6), decreased ABP with decreased HR 119 
(n=1), or increased HR (n=2, the ABP reading could not be obtained in this case). The 120 
details of atracurium administration and the observed effects are shown in Table 1. Peri-121 
operatively, either metoclopramide alone (Plasil, Lepetit UK; n=2) or a combination of 122 
metoclopramide and ranitidine (Zantac, GlaxoSmithKline UK; n=9) were administered IV 123 
in 11 out of 14 rabbits to prevent the occurrence of gastrointestinal disturbances. 124 
Anesthesia lasted 180 ± 62 minutes (Table 1). After the completion of each surgery, 125 
neostigmine (Neostigmine Methylsulfate Injection, Hameln Pharmaceuticals UK; total 126 
dose: 0.02 [0.01-0.045] mg/kg) and glycopyrronium (Glycopyrronium Bromide, Accord 127 
Healthcare UK; total dose range: 0.01 [0.01-0.02] mg/kg) were administered 128 
simultaneously IM, as soon as at least two out of 4 muscular twitches could be elicited by 129 
the nerve stimulator. Twelve out of 14 rabbits received a single dose of neostigmine, which 130 
was 0.01 mg/kg in 10 cases and 0.02 mg/kg in 2 cases. Two of the rabbits that had received 131 
0.01 mg/kg required additional neostigmine to achieve full recovery from the 132 
neuromuscular block. Of these two rabbits, one received an additional 0.01 mg/kg 20 133 
minutes after the first dose, while the other received an additional 0.05 mg/kg, followed by 134 
doses of 0.01 and 0.02 mg/kg given at 20 minute-intervals. The rectal temperature recorded 135 
at recovery was 36.4 ± 2 °C. Despite the continuous use of active warming throughout 136 
anesthesia, postoperative hypothermia (rectal temperature < 37.7 ºC)3 was recorded in 8 137 
out of 14 rabbits. Of these, two rabbits that were severely hypothermic at the end of the 138 
anesthetic (rabbit 1 = 30.3°C and rabbit 4 = 33 °C; Table 1), had experienced a decrease in 139 
ABP after atracurium administration. One of these two rabbits had the longest anesthetic 140 
time (rabbit 1 = 242 minutes; Table 1), while in the other anesthesia lasted 200 minutes 141 
(rabbit 4; Table 1). There was no association between the temperature at the end of the 142 
anesthetic and the duration of anesthesia (Pearson correlation coefficient = -0.34; P = 143 
0.24). Rabbits 1 and 4 experienced a prolonged recovery characterized by slow increase in 144 
body temperature, which reached 37°C after 2 and 3 hours, respectively, after the end of 145 
anesthesia.  146 
Food intake was encouraged postoperatively through syringe feeding.  Once the rabbits 147 
were fully recovered from anesthesia, meloxicam (Metacam, Boerhinger Ingelheim UK; 148 
0.5 mg/kg) was administered IV as post-operative analgesia. Additional buprenorphine 149 
(0.02 mg/kg IV) was administered in 5 cases. Long-term complications were not observed.    150 
 151 
 152 
 153 
 154 
 155 
 156 
Table 1 157 
Table 1  Details of intra-operative atracurium administration and related cardiovascular effects in 11 out of 14 pet 
rabbits anaesthetized to undergo ophthalmic surgery  
 
Rabbit Anesthetic 
protocol 
Total 
atracurium  
(mg/kg, IV) 
Details of 
atracurium 
administration  
Agent/ 
ET 
range 
per 
cent 
Duration 
of 
anesthesia 
(minutes) 
Cardiovascular 
effects within 5 
minutes from 
atracurium 
administration /  
intra-operative 
complications 
End 
T 
(°C) 
1 BMKS 0.2  One single dose 
given at the 
beginning of 
surgery 
Sevo/  
1.9-3 
242 SAP (Doppler) 
decreased from 105 to 
75 mmHg and 
normalized within 20 
minutes 
HR remained 
unchanged (180 bpm) 
Intra-operative 
hypothermia  
33 
2 BMAS 0.15 Two doses, of 
0.1 and 0.05 
mg/kg, given at 
40 minute 
intervals 
Sevo/  
 
3-4.7 
200 SAP could not be 
measured (Doppler) 
Transient increase in 
HR (from 230 to above 
250 bpm) that lasted 20 
minutes after the first 
atracurium dose (0.1 
mg/kg) 
38.3 
3 BMAS 0.6 Four doses, of 
0.2 (n=2) and 
0.1 (n=2) 
mg/kg, given at 
20 minute 
intervals 
Sevo/  
2.1-2.9 
220 SAP could not be 
measured (Doppler) 
Transient increase in 
HR (from 250 to 320 
bpm) that lasted 20 
minutes, after the 
second atracurium dose 
(0.2 mg/kg) 
Intra-operative 
hypothermia 
36 
4 BMAS 0.5 Five doses (0.1 
mg/kg each), 
given at 20-30 
minute intervals 
Sevo/  
1.6-2.5 
200 SAP (Doppler) 
decreased from 140 to 
115 mmHg, and from 
145 to 120 mmHg, 
after first and second 
atracurium doses, 
respectively 
HR remained 
unchanged (160 bpm) 
Intra-operative 
hypothermia  
30.3 
5 BMKS 0.65 Three doses 
(0.3, 0.2 and 
then 0.15 
mg/kg), given at 
30-60 minute 
intervals 
Sevo/  
1.8-2.6 
180 Intra-operative 
hypotension: SAP, 
MAP and DAP 
(invasive measurement 
via auricular artery) 
decreased from 115 to 
85, from 90 to 60, and 
from 50 to 35 mmHg, 
respectively, and  
normalized within 20 
minutes 
35.6 
HR increased from 220 
to 240 bpm after the 
second (0.2 mg/kg) 
atracurium bolus, 
normalized within 20 
minutes  
Intra-operative 
hypothermia  
6 MedBMAS 0.5 Four doses, of 
0.2 (n=1) and 
0.1 (n=3) mg/kg 
given at 20-55 
minute intervals 
Sevo/  
1.9-3.1 
120 SAP (Doppler) 
decreased from 90 to 
20, and then from 150 
to 115 mmHg, after the 
first (0.2 mg/kg) and 
the second (0.1 mg/kg) 
atracurium boluses, 
respectively; the 
hypotension that 
occurred after the first 
bolus lasted 25 minutes 
despite IV fluid 
resuscitation (10 ml/kg  
Lactated ringer and 5 
ml/kg 4% succinylated 
gelatin Ringer’s 
solution, IV) and 
ephedrine 
administration (0.1 
mg/kg IV) 
HR remained 
unchanged (180 bpm)  
39.1 
7 BMAS 0.4 Two doses of 
0.2 mg/kg, 
given at 70 
minute intervals 
Sevo/  
1.9-3.1 
208 SAP (Doppler) 
decreased from 110 to 
90 mmHg after the first 
atracurium bolus and 
normalized within 10 
minutes 
HR remained 
unchanged (200 bpm) 
Intra-operative 
hypothermia 
36.2 
8 MedBMAS 0.5 Four doses, of 
0.2 (n=1) and 
0.1 (n=4) 
mg/kg, given at 
20-45 minute 
intervals 
Sevo/  
1.9-2.6 
190 Intra-operative 
hypotension: SAP 
(Doppler) decreased 
from 95 to 22 mmHg 
after the first (0.2 
mg/kg) atracurium 
bolus; hypotension 
lasted 25 minutes 
despite fluids 
resuscitation (10 ml/kg 
Hartmann’s solution 
and 5 ml/kg 6% 
tetrastarch solution, IV) 
and ephedrine 
administration (0.1 
mg/kg IV) 
HR remained 
unchanged 
39.1 
9 MedBMAI 0.3 Three doses, of 
0.1 mg/kg each, 
Iso/  
1.1-1.4 
125 Intra-operative 
hypotension: SAP 
(Doppler) decreased 
36.5 
given at 20-60 
minute intervals 
from 100 to 60 mmHg 
after the second 
atracurium bolus (0.1 
mg/kg); hypotension 
lasted 25 minutes 
despite IV fluid 
resuscitation (5 ml/kg 
Hartmann’s solution, 
IV) and ephedrine 
administration (0.05 
mg/kg IV) 
HR decreased from 250 
to 230 bpm and lasted 
25 minutes after the 
second atracurium 
bolus  
Intra-operative 
hypothermia 
10 MedBMAI 0.6 Five doses, of 
0.2 (n=1) and 
0.1 (n=5) 
mg/kg, given at 
20-70 minute 
intervals 
Iso/  
1.1-1.9 
150 SAP (Doppler) 
decreased from 90 to 
60 mmHg, and from 
110 to 90 mmHg, after 
the first (0.2 mg/kg) 
and the second (0.1 
mg/kg) atracurium 
boluses, respectively; 
the effect lasted for 20 
minutes after each 
bolus 
HR remained 
unchanged (190 bpm) 
Intra-operative 
hypothermia 
36.8 
11 MedBMAS 0.75 Five doses, of 
0.2 (n=2), 0.1 
(n=3) and 0.05 
mg/kg (n=1), 
given at 15-40 
minute intervals 
Sevo/ 
2.2-3.1 
155 SAP (Doppler) 
decreased from 150 to 
130 mmHg, and from 
170 to 70 mmHg, after 
the first (0.2 mg/kg) 
and the second (0.1 
mg/kg) atracurium 
bolus, respectively; the 
effect lasted for 20 
minutes after each 
bolus 
HR remained 
unchanged (200 bpm) 
Intra-operative 
hypothermia 
36 
 158 
Table legend 159 
B: buprenorphine; M: midazolam; K: ketamine; Sevo: sevoflurane; Iso: isoflurane; A: Alfaxalone; Med: 160 
Medetomidine; ET: end-tidal concentration; SAP: systolic arterial pressure; MAP: mean arterial pressure: 161 
DAP: diastolic arterial pressure; HR: heart rate; bpm: beats per minute; end T (temperature): rectal body 162 
temperature measured at the end of general anaesthesia. Hypothermia and hypotension are defined as SAP < 163 
75 mmHg and rectal temperature < 37.4 ºC (Gallego 2017). 164 
Discussion 165 
The main finding of this retrospective investigation was that the intra-operative 166 
administration of atracurium to pet rabbits undergoing ocular surgery resulted in decreased 167 
ABP in the majority of the patients, and that this effect, although transient and self-168 
limiting, was in some cases profound and refractory to treatment with fluids and 169 
vasopressors. Another interesting finding is that the two most severe episodes of 170 
hypotension were observed in rabbits that had received a first, relatively low-dose of 171 
atracurium, which supports the assumption that this effect may not be dose-dependent.  172 
In all the 14 rabbits, the observed cardiovascular changes occurred within 5 minutes 173 
from the administration of atracurium. Moreover, in 8 of these rabbits the physiological 174 
response occurred before the beginning of surgery, when the mechanical stimulation of the 175 
eye globe had not started yet, which rules out a possible role of the oculocardiac reflex in 176 
causing the decrease in ABP. This supports the hypothesis of a causal, rather than only 177 
temporal association between the NMBA and the physiological response.  178 
Atracurium is known to cause vasodilation – and, possibly, hypotension - in various 179 
animal species, through release of histamine into the bloodstream.4 The vasodilation may 180 
trigger a baroreceptor reflex, which ultimately results in tachycardia as an attempt of the 181 
heart to compensate, and therefore prevent the cardiac output from decreasing critically.5 182 
Interestingly, in 6 of the 9 rabbits that experienced decrease in ABP after atracurium 183 
injection the heart rate remained unchanged and even decreased in one subject. This 184 
unusual finding may be explained by the peculiar physiology of the baroreceptor reflex of 185 
rabbits, in which hypotension can elicit a complex autonomic response which involves 186 
both the sympathetic and the parasympathetic components.6,7 Clinically, the net result of 187 
this complex interaction may be tachycardia, unchanged heart rate, or even bradycardia.  188 
Severe hypothermia was observed in two of the patients of this report. In these two 189 
rabbits, both of which had experienced decrease in ABP following atracurium 190 
administration, the rectal body temperature decreased steadily during surgery despite the 191 
use of active warming devices and was critically low at the end of the anesthetic. Owing to 192 
a large surface area to body mass ratio and a high basal metabolism, rabbits are particularly 193 
prone to develop hypothermia during Anesthesia.8 Inhalational anesthetic agents are 194 
known to further contribute to intra-operative hypothermia by inhibiting central 195 
thermoregulatory control and by causing arterial and venous vasodilation,9,10 which 196 
facilitates the dissipation of body heat through redistribution of the latter from the body 197 
core to the periphery. It is possible that atracurium exacerbated the drop in body 198 
temperature leading to severe hypothermia in some cases, by enhancing the vasodilatory 199 
effect of the anesthetic gases used.  200 
One recent study demonstrated that rabbits require sevoflurane ET concentrations of 3.9 201 
± 0.2 to maintain unconsciousness in the absence of nociceptive stimulation.11 The delivery 202 
of sevoflurane and isoflurane in the rabbits of the current investigation was titrated to 203 
effect at the discretion of the anesthetist in charge, based on the results of the clinical 204 
monitoring of each patient. This resulted in sevoflurane end tidal concentrations that were 205 
slightly lower than those reported by Terada and colleagues, a finding that can be 206 
explained by the concomitant use of other anesthetic and analgesic drugs that presumably 207 
decreased the MAC of sevoflurane.  208 
The choice of timing and dosing of neostigmine to reverse the block was also at the 209 
anesthesists’ discretion, and different clinicians opted for different doses, within the 210 
recommended dose-range, based on the total dose of atracurium received by each rabbit. 211 
However, all the anesthesists chose to administer the reversal agent IM, and only when at 212 
least two out of 4 twitches were elicited by the nerve stimulator. This is in agreement with 213 
the guidelines published for human patients that recommend not to administer neostigmine 214 
when the block is still profound.12 215 
In conclusion, hypotension and, possibly, hypothermia are likely intra-operative 216 
complications when clinical doses of atracurium are administered to pet rabbits. Extra care 217 
should be taken in the presence of underlying conditions that may exacerbate the 218 
cardiovascular effects of atracurium, namely hypovolemia, compromised cardiac function, 219 
high risk of intra-operative haemorrhage and concomitant use of inhalational anesthetic 220 
agents. 221 
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